pPACK-SPIKE™ B.1.429 (CAL.20C) Variant Spike Protein Lentivector Packaging Mix

Study the spike protein from SARS-CoV-2 Variant B.1.429 (CAL.20C) with this packaging mix for lentivirus pseudotyped with the B.1.429 spike protein
  • Based on SBI’s popular and highly cited pPACKH1 Packaging System
  • Uses codon-optimized SARS-CoV-2 “S” protein from Variant B.1.429, also called CAL.20C, in place of VSV-G envelope protein
  • Spike protein mutations are S13I, W152C, L452R, D614G
  • Ideal for vaccine and antiviral efficacy studies under BSL2 conditions
  • Package any 3rd-generation lentivector reporter of your choice, including SBI’s popular LentiLabeler reporters

Products

Catalog Number Description Size Price Quantity Add to Cart
CVD19-610A-1 pPACK-SPIKE B.1.429, SARS-CoV-2 “S” Pseudotype – B.1.429 (CAL.20C) Variant – Lentivector Packaging Mix 10 Reactions $702
- +
CVD19-615A-1 pPACK-SPIKE B.1.429, SARS-CoV-2 “S” Pseudotype – B.1.429 (CAL.20C) Variant – Lentivector Packaging Mix 25 Reactions $1399
- +
CVD19-619A-KIT pPACK-SPIKE B.1.429 Combo Kit, includes Cat# CVD19-610A-1, plus PureFection Transfection Reagent (Cat# LV750A-1) and PEG-it Virus Concentration solution(Cat# LV810A-1) 1 Kit $1183
- +

Overview

Overview

Safely study the spike protein from emerging SARS-CoV-2 variants  As potentially more transmissible variants of SARS-CoV-2 emerge, understanding how mutations in the spike protein impact SARS-CoV-2 behavior is critical. With the pPACK-SPIKE™ B.1.429 (CAL.20C) Variant Spike Protein Lentivector Packaging Mix, you can safely characterize the SARS-CoV-2 S1 spike protein from the highly transmissible lineage B.1.429 (also referred to as CAL.20C) [1], which has the following mutations in the spike protein:
  • S13I
  • W152C
  • L452R
  • D614G

Designed to efficiently package most third-generation lentivectors, the pPACK-SPIKE B.1.429 (CAL.20C) Variant Spike Protein Lentivector Packaging Mix speeds and simplifies preparation of lentiviral particles pseudotyped with the SARS-CoV-2 S13I, W152C, L452R, D614G spike glycoprotein, making it an ideal reagent for vaccine and antiviral drug discovery projects.

Based on SBI's highly cited pPACKH1 packaging system but with a truncated SARS-CoV-2 S13I, W152C, L452R, D614G Spike protein [2] replacing the standard VSV-G envelope protein, the pPACK-SPIKE B.1.429 (CAL.20C) Variant Spike Protein Packaging Mix consists of three plasmids that produce all of the structural and  replication proteins needed to transcribe and package an RNA copy of an expression lentivector into recombinant, S13I, W152C, L452R, D614G “Spike” pseudotyped lentiviral particles. As a result, you can conduct a range of SARS-CoV-2 studies under BSL-2 conditions, including neutralization assays, studies of virus interactions with host surface proteins, and the development of vaccines and therapeutics.

For added convenience we also offer pPACK-BALD™, an envelope protein-free lentivector packaging mix that can be used as a negative control for any pPACK-SPIKE study, or for creating lentivirus particles pseudotyped with the envelope protein of your choice.

  • Based on SBI’s popular and highly cited pPACKH1 Packaging System
  • Uses codon-optimized SARS-CoV-2 “S” protein from Variant B.1.429, also called CAL.20C, in place of VSV-G envelope protein
  • Spike protein mutations are S13I, W152C, L452R, D614G
  • Ideal for vaccine and antiviral efficacy studies under BSL2 conditions
  • Package any 3rd-generation lentivector reporter of your choice, including SBI’s popular LentiLabeler reporters
  • Compare with our full range of pPACK-SPIKE S protein pseudotyped lentiviruses to better understand emerging variants
  • Use with pPACK-BALD™, an envelope protein-free lentivector packaging system that is an ideal negative control

pPACK-SPIKE B.1.429 (CAL.20C) Variant Spike Protein Lentivector Packaging Mix is available as stand-alone packaging mixes with sufficient plasmids for 10 reactions (standard size) or 25 reactions (XL), as well as in a convenient kit format that includes PureFection™ Transfection Reagent and PEG-it Virus Precipitation Solution.

See all of the available pPACK-SPIKE S protein variants:

Catalog NumberProduct DescriptionSPIKE PROTEIN MUTATION
CVD19-500A-1pPACK-SPIKE SARS-CoV-2 “S” Pseudotype Lentivector Packaging MixOriginal Wuhan-Hu-1 strain
CVD19-590A-1pPACK-SPIKE Alpha (B.1.1.7), SARS-CoV-2 "S" Pseudotype - Alpha (B.1.1.7, UK) Variant - Lentivector Packaging MixΔH69/V70, ΔY144, N501Y, A570D, D614G, P681H, T716I, S982A, D1118H
CVD19-640A-1pPACK-SPIKE Beta (B.1.351), SARS-CoV-2 "S" Pseudotype - Beta (B.1.351) Variant - Lentivector Packaging MixL18F, D80A, D215G, Δ242-244, R246I, K417N, E484K, N501Y, D614G, A701V
CVD19-650A-1pPACK-SPIKE Delta (B.1.617.2), SARS-CoV-2 "S" Pseudotype - Delta (B.1.617.2) Variant - Lentivector Packaging MixT19R, G142D, ΔE156-157, R158G, L452R, T478K, D614G, P681R, D950N
CVD19-630A-1pPACK-SPIKE Gamma (P1), SARS-CoV-2 "S" Pseudotype - Gamma (P1) Variant - Lentivector Packaging MixL18F, T20N, P26S, D138Y, R190S, K417T, E484K, N501Y, D614G, H655Y, T1027I, V1176F
CVD19-660A-1pPACK-SPIKE Omicron (B.1.1.529), SARS-CoV-2 "S" Pseudotype - Omicron (B.1.1.529) Variant - Lentivector Packaging MixA67V, Δ69-70, T95I, Δ142-144, Y145D, Δ211, L212I, ins214EPE, G339D, S371L, S373P, S375F, K417N, N440K, G446S, S477N, T478K, E484A, Q493R, G496S,Q498R, N501Y, Y505H, T547K, D614G, H655Y, N679K, P681H, N764K, D796Y, N856K, Q954H, N969K, L981F
CVD19-530A-1pPACK-SPIKE D614G, SARS-CoV-2 “S” Pseudotype – D614G Mutant – Lentivector Packaging MixD614G
CVD19-560A-1pPACK-SPIKE N501Y, SARS-CoV-2 "S" Pseudotype - N501Y Mutant - Lentivector Packaging MixN501Y
CVD19-610A-1pPACK-SPIKE B.1.429, SARS-CoV-2 "S" Pseudotype - B.1.429 (CAL.20C) Variant - Lentivector Packaging MixS13I, W152C, L452R, & D614G
CVD19-620A-1pPACK-SPIKE B.1.525, SARS-CoV-2 "S" Pseudotype - B.1.525 Variant - Lentivector Packaging MixΔH69/V70, Q52R, E484K, D614G, Q677H, & F888L
CVD19-580A-1pPACK-SPIKE B.1.351 RBD Mutations Lentivector Packaging MixK417N, E484K, & N501Y
CVD19-600A-1pPACK-SPIKE B.1.351 S1 Mutations (RBD+D614G) Lentivector Packaging MixK417N, E484K, N501Y, & D614G
LV550A-1pPACK-BALD™ (Negative Control Packaging Mix)An envelope protein-free negative control for pPACK-SPIKE
References
  1. Deng X, et al. Transmission, infectivity, and antibody neutralization of an emerging SARS-CoV-2 variant in California carrying a L452R spike protein mutation. BioRxiv. 2021 March 09. doi: https://doi.org/10.1101/2021.03.07.21252647.
  2. Ou X, et al. Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV. Nat. commun. 2020 Mar 2711(1):1620. doi: 10.1038/s41467-020-15562-9. PMCID: PMC7100515.

References

How It Works

How It Works

pPACK-SPIKE is easy to use—simply co-transfect the pPACK-SPIKE Plasmids and your lentivector construct into 293TN producer cells or other lentiviral production cells, isolate pseudoviral particles with an optional concentration step, and conduct your studies.  width=

Supporting Data

Supporting Data

To see data generated using the pPACK-SPIKE with the S protein from the original Wuhan-Hu-1 strain, visit the pPACK-SPIKE  page.

FAQs

Resources

Citations

pPACK-SPIKE™ B.1.429 (CAL.20C) Variant Spike Protein Lentivector Packaging Mix $702.00

Products

Catalog Number Description Size Price Quantity Add to Cart
CVD19-610A-1 pPACK-SPIKE B.1.429, SARS-CoV-2 “S” Pseudotype – B.1.429 (CAL.20C) Variant – Lentivector Packaging Mix 10 Reactions $702
- +
CVD19-615A-1 pPACK-SPIKE B.1.429, SARS-CoV-2 “S” Pseudotype – B.1.429 (CAL.20C) Variant – Lentivector Packaging Mix 25 Reactions $1399
- +
CVD19-619A-KIT pPACK-SPIKE B.1.429 Combo Kit, includes Cat# CVD19-610A-1, plus PureFection Transfection Reagent (Cat# LV750A-1) and PEG-it Virus Concentration solution(Cat# LV810A-1) 1 Kit $1183
- +

Overview

Overview

Safely study the spike protein from emerging SARS-CoV-2 variants  As potentially more transmissible variants of SARS-CoV-2 emerge, understanding how mutations in the spike protein impact SARS-CoV-2 behavior is critical. With the pPACK-SPIKE™ B.1.429 (CAL.20C) Variant Spike Protein Lentivector Packaging Mix, you can safely characterize the SARS-CoV-2 S1 spike protein from the highly transmissible lineage B.1.429 (also referred to as CAL.20C) [1], which has the following mutations in the spike protein:
  • S13I
  • W152C
  • L452R
  • D614G

Designed to efficiently package most third-generation lentivectors, the pPACK-SPIKE B.1.429 (CAL.20C) Variant Spike Protein Lentivector Packaging Mix speeds and simplifies preparation of lentiviral particles pseudotyped with the SARS-CoV-2 S13I, W152C, L452R, D614G spike glycoprotein, making it an ideal reagent for vaccine and antiviral drug discovery projects.

Based on SBI's highly cited pPACKH1 packaging system but with a truncated SARS-CoV-2 S13I, W152C, L452R, D614G Spike protein [2] replacing the standard VSV-G envelope protein, the pPACK-SPIKE B.1.429 (CAL.20C) Variant Spike Protein Packaging Mix consists of three plasmids that produce all of the structural and  replication proteins needed to transcribe and package an RNA copy of an expression lentivector into recombinant, S13I, W152C, L452R, D614G “Spike” pseudotyped lentiviral particles. As a result, you can conduct a range of SARS-CoV-2 studies under BSL-2 conditions, including neutralization assays, studies of virus interactions with host surface proteins, and the development of vaccines and therapeutics.

For added convenience we also offer pPACK-BALD™, an envelope protein-free lentivector packaging mix that can be used as a negative control for any pPACK-SPIKE study, or for creating lentivirus particles pseudotyped with the envelope protein of your choice.

  • Based on SBI’s popular and highly cited pPACKH1 Packaging System
  • Uses codon-optimized SARS-CoV-2 “S” protein from Variant B.1.429, also called CAL.20C, in place of VSV-G envelope protein
  • Spike protein mutations are S13I, W152C, L452R, D614G
  • Ideal for vaccine and antiviral efficacy studies under BSL2 conditions
  • Package any 3rd-generation lentivector reporter of your choice, including SBI’s popular LentiLabeler reporters
  • Compare with our full range of pPACK-SPIKE S protein pseudotyped lentiviruses to better understand emerging variants
  • Use with pPACK-BALD™, an envelope protein-free lentivector packaging system that is an ideal negative control

pPACK-SPIKE B.1.429 (CAL.20C) Variant Spike Protein Lentivector Packaging Mix is available as stand-alone packaging mixes with sufficient plasmids for 10 reactions (standard size) or 25 reactions (XL), as well as in a convenient kit format that includes PureFection™ Transfection Reagent and PEG-it Virus Precipitation Solution.

See all of the available pPACK-SPIKE S protein variants:

Catalog NumberProduct DescriptionSPIKE PROTEIN MUTATION
CVD19-500A-1pPACK-SPIKE SARS-CoV-2 “S” Pseudotype Lentivector Packaging MixOriginal Wuhan-Hu-1 strain
CVD19-590A-1pPACK-SPIKE Alpha (B.1.1.7), SARS-CoV-2 "S" Pseudotype - Alpha (B.1.1.7, UK) Variant - Lentivector Packaging MixΔH69/V70, ΔY144, N501Y, A570D, D614G, P681H, T716I, S982A, D1118H
CVD19-640A-1pPACK-SPIKE Beta (B.1.351), SARS-CoV-2 "S" Pseudotype - Beta (B.1.351) Variant - Lentivector Packaging MixL18F, D80A, D215G, Δ242-244, R246I, K417N, E484K, N501Y, D614G, A701V
CVD19-650A-1pPACK-SPIKE Delta (B.1.617.2), SARS-CoV-2 "S" Pseudotype - Delta (B.1.617.2) Variant - Lentivector Packaging MixT19R, G142D, ΔE156-157, R158G, L452R, T478K, D614G, P681R, D950N
CVD19-630A-1pPACK-SPIKE Gamma (P1), SARS-CoV-2 "S" Pseudotype - Gamma (P1) Variant - Lentivector Packaging MixL18F, T20N, P26S, D138Y, R190S, K417T, E484K, N501Y, D614G, H655Y, T1027I, V1176F
CVD19-660A-1pPACK-SPIKE Omicron (B.1.1.529), SARS-CoV-2 "S" Pseudotype - Omicron (B.1.1.529) Variant - Lentivector Packaging MixA67V, Δ69-70, T95I, Δ142-144, Y145D, Δ211, L212I, ins214EPE, G339D, S371L, S373P, S375F, K417N, N440K, G446S, S477N, T478K, E484A, Q493R, G496S,Q498R, N501Y, Y505H, T547K, D614G, H655Y, N679K, P681H, N764K, D796Y, N856K, Q954H, N969K, L981F
CVD19-530A-1pPACK-SPIKE D614G, SARS-CoV-2 “S” Pseudotype – D614G Mutant – Lentivector Packaging MixD614G
CVD19-560A-1pPACK-SPIKE N501Y, SARS-CoV-2 "S" Pseudotype - N501Y Mutant - Lentivector Packaging MixN501Y
CVD19-610A-1pPACK-SPIKE B.1.429, SARS-CoV-2 "S" Pseudotype - B.1.429 (CAL.20C) Variant - Lentivector Packaging MixS13I, W152C, L452R, & D614G
CVD19-620A-1pPACK-SPIKE B.1.525, SARS-CoV-2 "S" Pseudotype - B.1.525 Variant - Lentivector Packaging MixΔH69/V70, Q52R, E484K, D614G, Q677H, & F888L
CVD19-580A-1pPACK-SPIKE B.1.351 RBD Mutations Lentivector Packaging MixK417N, E484K, & N501Y
CVD19-600A-1pPACK-SPIKE B.1.351 S1 Mutations (RBD+D614G) Lentivector Packaging MixK417N, E484K, N501Y, & D614G
LV550A-1pPACK-BALD™ (Negative Control Packaging Mix)An envelope protein-free negative control for pPACK-SPIKE
References
  1. Deng X, et al. Transmission, infectivity, and antibody neutralization of an emerging SARS-CoV-2 variant in California carrying a L452R spike protein mutation. BioRxiv. 2021 March 09. doi: https://doi.org/10.1101/2021.03.07.21252647.
  2. Ou X, et al. Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV. Nat. commun. 2020 Mar 2711(1):1620. doi: 10.1038/s41467-020-15562-9. PMCID: PMC7100515.

References

How It Works

How It Works

pPACK-SPIKE is easy to use—simply co-transfect the pPACK-SPIKE Plasmids and your lentivector construct into 293TN producer cells or other lentiviral production cells, isolate pseudoviral particles with an optional concentration step, and conduct your studies.  width=

Supporting Data

Supporting Data

To see data generated using the pPACK-SPIKE with the S protein from the original Wuhan-Hu-1 strain, visit the pPACK-SPIKE  page.

FAQs

Citations